康弘药业：子公司收到药物临床试验补充申请批准通知书

Core Viewpoint - Kanghong Pharmaceutical's subsidiary has been approved to conduct clinical trials for a high-dose version of Conbercept eye injection, a first-class biopharmaceutical innovation developed by Kanghong Biotech [1] Group 1: Product Information - Conbercept eye injection is a self-developed innovative drug by Kanghong Biotech, designed for injection [1] - The indications for Conbercept include neovascular (wet) age-related macular degeneration (nAMD) and vision impairment caused by macular edema due to retinal vein occlusion (RVO) [1] Group 2: Regulatory Approval - The National Medical Products Administration has approved the high-dose version of Conbercept for clinical trials, with acceptance numbers CXSB2500193 and CXSB2500194 [1]